AzurRx (AZRX) Corporate Media Kit

26 MS1819 Doses # Patients Safety Primary Efficacy Endpoints Secondary Efficacy Endpoints Status 2240 mg 32 U.S., Poland • CFA: MS1819 56% vs. PERT 86% • ~50% of patients reached non- inferiority • CNA: MS1819 93% vs. PERT 97% - no need for protease Completed 2019 MS1819 Phase 2 Cystic Fibrosis OPTION Bridging Dose Safety Study